About The Study

Atopic dermatitis (eczema) is a chronic condition that causes itchy and dry skin. Eczema is most common in children, but it can occur at any age. It is a long-lasting skin condition that tends to flare at different times. Atopic dermatitis symptoms can appear anywhere on the body and vary widely from person to person. Common symptoms can include dry, cracked skin, inflamed or swollen skin, itchiness, thickened skin, and more. People with atopic dermatitis are at risk of developing allergies, hay fever, asthma, and discolored, scaly skin.

Researchers are looking for adolescents and adults who identify as a race other than White with moderate-to-severe Atopic Dermatitis and a history of inadequate response to treatment with topical medications. The study will investigate the safety and effectiveness of the study drug to reduce the area and severity of eczema symptoms.

Study Criteria

To qualify, participants must:

Be at least 12 years of age
Identify as a race other than White
Have skin that, when exposed to the sun or UV rays, rarely or never burns and tans easily
Have a history of inadequate response to treatment with topical medications
Have chronic Atopic Dermatitis (Eczema) that has been present for at least 1 year prior to screening
Not have had prior treatment with dupilumab (DUPIXENT)
Not have had prior treatment with tralokinumab (Adbry)

Why Participate?

There is no cost to participate and health insurance is not required to participate. Eligible participants will receive the investigational drug and all study-related assessments and care at no cost. Compensation for time and travel may also be provided.

Question 1 of 5

Have you been diagnosed with Atopic Dermatitis (Eczema) or are you the parent of a child who has been diagnosed with Atopic Dermatitis?

Question 2 of 5

Do you or your child identify as a race other than White?

Question 3 of 5

When exposed to the sun or UV rays, does your or your child's skin rarely or never burn and tan easily?

Question 4 of 5

Have you or your child previously used topical mediations to treat Atopic Dermatitis that were not effective?

Question 5 of 5

Have you or your child previously used dupilumab (DUPIXENT) or tralokinumab (Adbry) to treat moderate-to-severe Atopic Dermatitis?

So far - So good!

To learn more about this study and how you can participate, fill out the form below for a study coordinator to contact you.

Choose a Location

Please select a research site near you. If you don't see a site near you, then select "The sites listed here are not convenient for me." Study locations are being added regularly. A study representative will call you if a research site becomes available in your area.

Avance Clinical Trials

27020 Alicia Pkwy, Suite G

Laguna Niguel, CA 92677

NaN Mi

Cura Clinical Research

38460 5th Street West, Suite G

Palmdale, CA 93551

NaN Mi

The sites listed here are not convenient for me.

We're sorry, but you are not eligible at this time...

You can also enter your information below if you would like to be contacted about future clinical research opportunities. Contact your healthcare provider if you have any medical questions. To see if you qualify for a similar study, please click here.